National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Sarilumab (Kevzara®) in combination with methotrexate (MTX) for the treatment of moderately to severely active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti-rheumatic drugs (DMARD). Sarilumab can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate.

 

NCPE Rapid Review Process Complete
Rapid review received 18/08/2017
Rapid review completed 04/10/2017
Rapid Review outcome Full pharmacoeconomic assessment recommended at the submitted price.